Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

Abstract: Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed is the use of these salts as adjuvants in parenteral vaccine formulations and adjuvant compositions, and to vaccine adjuvants comprising such salts.

Abstract: Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.

Abstract: The present disclosure relates to a cosmetic composition comprising, in an aqueous medium, at least one film-forming polymer, at least one aqueous microdispersion of wax, and at least one water-soluble aromatic acid ester that is liquid at room temperature. The present disclosure also relates to the process for cosmetically treating keratinous materials, such as the skin, comprising applying said composition to keratinous materials. The composition is easy to apply on keratinous materials and forms a glossy and non-sticky film.

Abstract: The invention relates to the use of 3-deazaadenosine and analogs thereof for the manufacture of a medicament against vascular diseases or graft rejection.

Abstract: A medical device for placement at a site in a patient's body and for controlling pH levels at the site in the patient's body includes one or more structural components made of a first biodegradable and/or bioabsorbable material or, alternatively, one or more structural components having a coating thereon made of a first biodegradable and/or bioabsorbable material. The device also includes a buffering agent and at least one second biodegradable and/or bioabsorbable material on or in the one or more structural components, or alternatively, on or in the coating on the one or more structural components. The at least one second biodegradable and/or bioabsorbable material encapsulates the buffering agent and the buffering agent is dispersed from the at least one second biodegradable and/or bioabsorbable material in response to hydrolysis of the first biodegradable and/or bioabsorbable material.

Abstract: A C-nitroso moiety derived from a carbon acid with a pKa less than about 25 is bound in a biocompatible polymer as an ester or ether to a pendant hydroxyl group, as an ester to a pendant carboxylic acid or as an amine or amide to a pendant amine moiety. The polymer with c-nitroso moiety bound thereto can be coated on a medical device and/or used for prophylaxis of a patient at risk for restenosis. A c-nitroso moiety bound as amide to polyisobutylene amine substituted styrene copolymer is described in detail.

Abstract: An open porous matrix of particulate material for in vivo use in or on a target tissue in medicine, the matrix comprising particles cross-linked with one another so as to define pores there between and uses therefor are described.

Abstract: Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.

Abstract: Individualized responsive dosing pharmanutrient systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a pharmanutrient system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, organics substrates, inorganic or synthetic substrates, biological components, and/or other nutrients incorporated or provided with a pharmacologically active ingredient in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different pharmanutrient based on varying desired biological response within each dosing period.

Abstract: The present invention is a composition containing cholesterol lowering and blood lipids lowering components such as phytosterols in a biologically easily available form in combination with unsaturated fatty acids or esters, short chain fatty acids or esters and/or hydrolyzed flour containing ?-glucan and amylodextrin; food containing such a composition and a method for manufacturing of such a composition.

Abstract: The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Abstract: An adhesive patch for percutaneous fentanyl administration which is easily produced, has long-term continuity, and is excellent in adhesion and conformability to the skin. The adhesive patch comprises a backing layer and a pressure-sensitive adhesive layer formed on one side thereof, wherein the pressure-sensitive adhesive layer comprises fentanyl as an active ingredient, a pressure-sensitive adhesive base, and a tackifier resin, the pressure-sensitive adhesive base comprising polyisobutylene and a styrene/isoprene/styrene block copolymer, the proportion of the polyisobutylene in the adhesive base being, 8 to 15 wt. %, and the ratio of the concentration of the polyisobutylene to that of the styrene/isoprene/styrene block copolymer being from 2:3 to 3:2.

Abstract: A cosmetic treatment process is provided herein useful for reducing fine lines, wrinkles, or fine lines and wrinkles. The process comprises contacting a composition to an area of the skin or tissue of a subject, wherein the composition comprises a substance encapsulated within a lipid vesicle comprising a lipid having one or more polyethylene glycol (PEG) chains. The lipid vesicle has a charged surface, and an electric voltage is applied directly to the area of the skin that is contacted with the composition, whereby fine lines, wrinkles, or fine lines and wrinkles are reduced.

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Abstract: A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 ?m, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, retains the full activity of the active ingredient, and when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an in vivo environment the active ingredient in a controlled manner over a long period.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Abstract: The present invention relates to specific DL-lactide-?-caprolactone copolymers and the application of these polymers in the production of biodegradable medical applications. According to the present invention a polymeric material comprising poly(DL-lactide-co-?-caprolactone) is provided, which is obtained by the copolymerization of DL-lactide and ?-caprolactone, having a lactide content of 51-75 mol %, most preferably of 62-69 mol %. The materials of the present invention have excellent mechanical properties and may be used to provide articles for medical application, in particular nerve guides.

Abstract: The present invention relates to an adsorbate, comprising an adsorbent and bicalutamide adsorbed on said adsorbent, a process for preparing same, and a pharmaceutical composition thereof.

Abstract: Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.

Abstract: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.

Abstract: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods for making DBM bone products, wherein both the DBM and a mineralized gelatin carrier for the DBM are derived independently from a bone lot.

Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Lactobacilli.

Abstract: A first subject of the present invention is an insoluble powder characterized in that a zeta-potential is a negative value. It is preferable that barium sulfate is a main ingredient in the insoluble powder. It is preferable that an average primary particle diameter is 3 to 100 ?m, and an aspect ratio is 3 to 250 in the insoluble powder. It is preferable that the insoluble powder is a metal-doped barium sulfate powder obtained by reacting a barium ion and a sulfate ion in the presence of a metal ion. It is preferable that the metal ion is one or more selected from the group consisting of a lithium ion, a sodium ion and a zinc ion in the insoluble powder. A second subject of the present invention is a skin barrier function recovering powder, or a skin roughening preventing and improving powder, which comprises the aforementioned powder. A third subject of the present invention is a skin external composition characterized in that a content of the aforementioned powder is 1 to 40% by weight.

Abstract: Disclosed is a novel herbal composition for maintaining/caring the skin around the eye, the composition comprising extracts of Saxifraga ligulata syn. Bergenia ligulata, Cipadessa baccifera and Emblica officinalis and cosmeceutical excipients thereof. Also disclosed is a method of extraction, delivery system comprising the same and use thereof.

Abstract: Disclosed herein an herbal acne control compositions comprising extracts of Swietenia mahagoni, Salix tetrasperma, Aloe vera and Curcuma longa and pharmaceutically acceptable excipients. Also disclosed are the methods of making the composition, formulating the same into different delivery systems and use thereof for the prevention of acne related skin disorders in human beings.

Abstract: A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells.

Abstract: Disclosed is an effervescent composition that includes an effervescent agent and cranberry extract, preferably in an amount sufficient to decrease the measurable amount of bacteria present in the urine of an individual having a urinary tract infection.

Abstract: A method of keeping an alcoholic beverage in an open topped vessel cool, said beverage comprising a water content and a dissolved gas content, and said method comprising forming ice in the beverage in the open-topped vessel said ice having a cooling effect on the beverage, said ice being formed in the beverage from water of said water content.

Abstract: The manufactured mineral water of this invention is made from biologically acceptable soluble salts of four different groups which may be made separately. Group A elements consist of calcium at a final concentration of between 25 and 82 mg/L and magnesium at a final concentration of between 6 and 18 mg/L. Group B elements consist of phosphorus at a final concentration of between 15 and 80 mg/L, potassium at a final concentration of between 50 and 180 mg/L, silicon at a final concentration of between 0.45 to 1.5 mg/L, sodium at a final concentration of between 3 and 30 mg/L, chlorine at a final concentration of between 3 and 28 mg/L. Group C elements consist of boron at a final concentration of between 0 and 60 ?g/L, chromium at a final concentration of between 0 and 0.5 ?g/L, cobalt at a final concentration of between 0 and 0.5 ?g/L, copper at a final concentration of between 0 and 12 ?g/L, iodine at a final concentration of between 0 and 6 ?g/L, lithium at a final concentration of between 0 and 1.

Abstract: The present invention related to a preparing method of retort roast chestnuts using far infrared ray thawing, more particularly a preparing method characterized in that it comprises a step of ageing a harvested chestnuts by storing in the state of refrigeration to increase sugar content; roasting said aged chestnuts at 170˜200° C. during 5˜10 minutes to increase its taste and flavor; peeling and then washing followed by rapid freezing it; thawing frozen chestnuts by far infrared ray at 170˜230° C. during 30˜60 minutes to inhibit generation of microorganism and remove generation of an extraordinary taste or smell and deformity during a processing procedure; and pasteurizing with multi-steps after packing thawed chestnuts with a nitrogen substitution to minimize degradation of texture.

Abstract: A method of producing a food product such as a colored veined cheese product includes providing a cheese curd to which a flavorant is added. The cheese curd and the flavorant are worked into a homogenous mixture. A colored vein mimetic is added to the homogeneous mixture in an amount for a time sufficient to produce the colored veins within the cheese product such that the cheese product has a flavor and an appearance of a naturally veined cheese.

Abstract: The present invention relates to a process of producing an oil composition by blending and fractionation steps and the oil composition obtained therefrom. The invention is directed to any vegetable oils such as palm oil, palm olein or palm stearin blends with unsaturated oils of soybean, corn, canola, rapeseed, sunflower oil, where the oleic content is more than 20% and the linoleic and linolenic contents are more than 30%. The new liquid oil is clear and is used as salad oils, cooking oils, etc. The stearins from such blends are of use in margarine and shortenings.

Abstract: The invention relates to a compressible, powdery sugar composition having an apparent density of more than 0.5, especially 0.6 and approximately 0.8, preferably equal to 0.6, said composition consisting of hollow particles. The invention also relates to a method for preparing a compressible sugar solution, comprising a drying stage involving the atomization of an initial saccharose solution with at least one added anti-crystallizing agent, wherein the saccharose content of the initial saccharose solution is lower than the saturation rates, advantageously exhibiting a dry matter rate of approximately 60 wt. % in relation to the total weight of the composition.

Abstract: A method of providing an antioxidant to a medical device is described.

Abstract: An adherent bioactive calcium phosphate coating is formed on a titanium or titanium alloy substrate by immersing the substrate in an acidic calcium phosphate solution to form a non-apatitic calcium phosphate coating on the substrate. In a second step the coated substrate can be converted to a less reactive coating by being immersed into a basic or neutral solution to convert the coating into an apatite. However if a relatively reactive coating is desired, the second step can be dispensed with.

Abstract: Disclosed herein are a protein chip substrate and a method for manufacturing the protein chip substrate. The method includes deposition of plasma polymerized ethylenediamine (PPEDA) having an amine group on plasma polymerized cyclohexnane (PPCHex) by inductively coupled plasma-chemical vapor deposition (ICP-CVD), thereby preventing non-specific adsorption of proteins on a slide surface.

Abstract: Water soluble, gelatin-free dip coatings for pharmaceutical solid dosage forms such as tablets comprising HPMC and xanthan gum, carrageenan, and mixtures thereof, or HPMC and castor oil or maltodextrin.

Abstract: System and method for coating a medical appliance is provided. In accord with one embodiment, a system for applying a coating to a medical appliance having accessible patterned surfaces is provided. The system may include: a processor, an appliance support, and a solenoid type fluid dispensing head having an electromagnetically controlled valve. In the system, the appliance support may be adapted to hold the medical appliance and to provide direct access for a coating to contact the exposed external patterned surfaces of the medical appliance. The solenoid type fluid dispensing head in this system may move with respect to the medical appliance and may be in communication with a source of coating and with the processor. The processor in this system may contain commands that instruct the solenoid type fluid dispensing head to force coating onto the accessible patterned surfaces of the medical appliance in a pattern that correlates with the accessible patterned surfaces of the medical appliance.

Abstract: The present invention relates to method and apparatus for dispensing a beneficial agent into an expandable medical device. The method includes the step of placing an expandable medical device on a support and dispensing a beneficial agent into a plurality of openings in the medical device with a shield gas for controlling a local environment surrounding the dispenser.

Abstract: A process for producing a cosmetic-impregnated sheet which comprises applying and infiltrating a cosmetic base to and into a base sheet having on the surface thereof a retentive sheet capable of absorbing and retaining the cosmetic base at a shear rate of 102 to 106 s?1, the cosmetic base being applied to and infiltrated into the retentive sheet of the base sheet, and the cosmetic base, when subjected to a steady shear deformation at a shear rate of 2 s?1 for 100 seconds followed by a steady shear deformation at a stepwise increased shear rate of 20 s?1, showing no shear stress growth or showing such a shear stress growth that the difference between the peak shear stress B at a shear rate of 20 s?1 and the equilibrium shear stress A at the same shear rate, B?A, is 20% or smaller of the equilibrium shear stress A in the transition between the two shear rates.

Abstract: A liquid crystal dispensing system includes a container to contain liquid crystal to be dispensed, a discharge pump to receive the liquid crystal from the container and to discharge the liquid crystal, a nozzle to dispense the liquid crystal discharged from the discharge pump onto a substrate, and a control unit to control a dispensing amount of liquid crystal discharged from the discharge pump and to compensate the dispensing amount when the dispensing amount of liquid crystal exceeds a limitation value.

Abstract: The present invention provides electroactive polymers, transducers and devices that maintain pre-strain in one or more portions of an electroactive polymer. Electroactive polymers described herein may include a pre-strained portion and a stiffened portion configured to maintain pre-strain in the pre-strained portion. One fabrication technique applies pre-strain to a partially cured electroactive polymer. The partially cured polymer is then further cured to stiffen and maintain the pre-strain. In another fabrication technique, a support layer is coupled to the polymer that maintains pre-strain in a portion of an electroactive polymer. Another embodiment of the invention cures a polymer precursor to maintain pre-strain in an electroactive polymer.

Abstract: A first population of semiconductor nanocrystals to create electron transport conduits, a second population so semiconductor nanocrystals to create hole transport conduits; and a third population of semiconductor nanocrystals to be used for either light absorption or light emission can be combined to form an inorganic nanostructure layer.

Abstract: A method for forming a metal wiring structure includes: (i) providing a multi-layer structure including an exposed wiring layer and an exposed insulating layer in a reaction space; (ii) introducing an —NH2 or >NH terminal at least on an exposed surface of the insulating layer in a reducing atmosphere; (iii) introducing a reducing compound to the reaction space and then purging a reaction space; (iv) introducing a metal halide compound to the reaction space and then purging the reaction space; (v) introducing a gas containing N and H and then purging the reaction space; (vi) repeating steps (iii) to (v) in sequence to produce a metal-containing barrier layer; and (vii) forming a metal film on the metal-containing barrier layer.

Abstract: A method of manufacturing an orientation film which method is suitable for manufacturing an orientation film containing a ceramic at low cost. The method includes the steps of: (a) forming a ceramic film on a seed substrate in which crystal orientation is controlled at least on a surface thereof by using an aerosol deposition method of injecting powder toward a substrate and depositing the powder on the substrate; and (b) heat-treating the ceramic film formed at step (a) to form an orientation film in which crystal grains contained in the ceramic film is oriented.

Abstract: A process for the preparation of polymer magnetic particles, which comprises: providing polymer particles having a porous interior, and contacting the polymer particles with a magnetic fluid comprising a homogeneous dispersion of magnetic particles, whereby the magnetic particles are incorporated into the porous interior to produce polymer magnetic particles.